AXDX
NASDAQAccelerate Diagnostics Inc.
SectorIndustrialsIndustryBiotechnology: Laboratory Analytical Instruments
Latest news
25 items- SECAccelerate Diagnostics Inc. filed SEC Form 8-K: Leadership Update8-K - Accelerate Diagnostics, Inc (0000727207) (Filer)
- SECSEC Form NT 10-Q filed by Accelerate Diagnostics Inc.NT 10-Q - Accelerate Diagnostics, Inc (0000727207) (Filer)
- SECAccelerate Diagnostics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Accelerate Diagnostics, Inc (0000727207) (Filer)
- SECAccelerate Diagnostics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Events That Accelerate or Increase a Direct Financial Obligation, Regulation FD Disclosure, Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - Accelerate Diagnostics, Inc (0000727207) (Filer)
- PRAccelerate Diagnostics Files for Chapter 11 Protection and Agrees to Terms to Sell Substantially All AssetsTUCSON, Ariz., May 8, 2025 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) ("Accelerate" or the Company") today announced that it has voluntarily initiated a Chapter 11 restructuring proceeding in the United States Bankruptcy Court for the District of Delaware ("Bankruptcy Court") and will seek to sell its assets through a court supervised sale process. Accelerate has filed various "first day" motions with the Bankruptcy Court requesting customary relief that will enable the Company to transition into Chapter 11 without material disruption to their ordinary course o
- INSIDERSEC Form 3 filed by new insider Shalhoub Paul Vincent3 - Accelerate Diagnostics, Inc (0000727207) (Issuer)
- SECAmendment: SEC Form 10-K/A filed by Accelerate Diagnostics Inc.10-K/A - Accelerate Diagnostics, Inc (0000727207) (Filer)
- SECAccelerate Diagnostics Inc. filed SEC Form 8-K: Leadership Update8-K - Accelerate Diagnostics, Inc (0000727207) (Filer)
- SECAccelerate Diagnostics Inc. filed SEC Form 8-K: Leadership Update8-K - Accelerate Diagnostics, Inc (0000727207) (Filer)
- INSIDERChief Executive Officer Phillips Jack converted options into 53,283 shares and sold $16,473 worth of shares (25,343 units at $0.65), increasing direct ownership by 17% to 191,374 units (SEC Form 4)4 - Accelerate Diagnostics, Inc (0000727207) (Issuer)
- INSIDERChief Technology Officer Mertz Larry Michael converted options into 4,298 shares and sold $990 worth of shares (1,523 units at $0.65), increasing direct ownership by 3% to 84,803 units (SEC Form 4)4 - Accelerate Diagnostics, Inc (0000727207) (Issuer)
- INSIDERChief Financial Officer Patience David converted options into 20,000 shares and sold $4,839 worth of shares (6,816 units at $0.71), increasing direct ownership by 26% to 64,568 units (SEC Form 4)4 - Accelerate Diagnostics, Inc (0000727207) (Issuer)
- SECAccelerate Diagnostics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Accelerate Diagnostics, Inc (0000727207) (Filer)
- PRAccelerate Diagnostics Submits WAVE System and Gram-Negative Positive Blood Culture Menu to the FDA for 510(k) ClearanceTUCSON, Ariz., March 21, 2025 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX), an innovator in rapid in vitro diagnostics for microbiology, today announced the submission of its Accelerate WAVE™ system and positive blood culture gram-negative test kit to the U.S. Food and Drug Administration (FDA) for 510(k) clearance. The Accelerate WAVE system is designed to provide rapid antimicrobial susceptibility testing (AST) directly from positive blood culture bottles and bacterial isolate colonies. The WAVE system is designed to deliver accurate results in an average of 4.
- SECAccelerate Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Accelerate Diagnostics, Inc (0000727207) (Filer)
- PRAccelerate Diagnostics Reports Fourth Quarter and Full-Year 2024 Financial ResultsTUCSON, Ariz., March 21, 2025 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today reports financial results for the fourth quarter and year ended December 31, 2024. 2024 Fourth Quarter Results Net sales for the quarter were $2.8 million, compared to $3.0 million for the same quarter of the prior year. The decline in revenues was primarily driven by lower sales of consumable products compared to the same period in the prior year.Gross margin was approximately 16% for the quarter, compared to approximately 21% for the same quarter of the prior year. The decline in
- SECSEC Form 10-K filed by Accelerate Diagnostics Inc.10-K - Accelerate Diagnostics, Inc (0000727207) (Filer)
- INSIDERChief Financial Officer Patience David converted options into 1,500 shares and sold $583 worth of shares (535 units at $1.09), increasing direct ownership by 2% to 51,384 units (SEC Form 4)4 - Accelerate Diagnostics, Inc (0000727207) (Issuer)
- INSIDERChief Executive Officer Phillips Jack converted options into 1,000 shares and sold $655 worth of shares (485 units at $1.35), increasing direct ownership by 0.32% to 163,434 units (SEC Form 4)4 - Accelerate Diagnostics, Inc (0000727207) (Issuer)
- SECAccelerate Diagnostics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Accelerate Diagnostics, Inc (0000727207) (Filer)
- SECAccelerate Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Accelerate Diagnostics, Inc (0000727207) (Filer)
- PRAccelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2024 ResultsTUCSON, Ariz., Jan. 10, 2025 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) (Accelerate), an in vitro diagnostics company dedicated to providing services that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections, today announced certain preliminary, unaudited results for the quarter and year ended December 31, 2024. "During the fourth quarter, we continued our momentum across our innovation pipeline with significant progress of the clinical trial for our Accelerate WAVE™ system and the Gram-Negative assay while also
- 13D/GAmendment: SEC Form SC 13D/A filed by Accelerate Diagnostics Inc.SC 13D/A - Accelerate Diagnostics, Inc (0000727207) (Subject)
- INSIDERDirector Patience John bought $314,000 worth of shares (200,000 units at $1.57) (SEC Form 4)4 - Accelerate Diagnostics, Inc (0000727207) (Issuer)
- INSIDERDirector Schuler Jack W sold $314,000 worth of shares (200,000 units at $1.57) (SEC Form 4)4 - Accelerate Diagnostics, Inc (0000727207) (Issuer)
AXDX FAQ
6 questionsWhat does Accelerate Diagnostics Inc. do?
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients...Where does AXDX stock trade?
Accelerate Diagnostics Inc. (AXDX) is listed on NASDAQ.What sector and industry is AXDX in?
Accelerate Diagnostics Inc. operates in the Industrials sector, Biotechnology: Laboratory Analytical Instruments industry.What are analysts saying about AXDX?
Accelerate Diagnostics Inc. has had 1 recent analyst action on file. The most recent action was from Craig-Hallum: Hold with a $500.00 price target on 2022-03-09. Recent price targets cluster around $500.00.What companies are similar to AXDX?
Notable peers in the same industry include A (Agilent Technologies Inc.), WAT (Waters Corporation), MTD (Mettler-Toledo International Inc.), PKI (PerkinElmer Inc.), RVTY (Revvity Inc.). Compare AXDX side-by-side with any of them on Quantisnow.How can I track AXDX on Quantisnow?
Quantisnow aggregates Accelerate Diagnostics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AXDX to receive live email and push alerts on every new disclosure.